Insulet Financials
PODD Stock | USD 261.63 6.19 2.42% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 3.4 | 3.5793 |
|
|
The essential information of the day-to-day investment outlook for Insulet includes many different criteria found on its balance sheet. An individual investor should monitor Insulet's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Insulet.
Net Income |
|
Insulet | Select Account or Indicator |
Insulet Earnings Geography
Please note, the presentation of Insulet's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Insulet's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Insulet's management manipulating its earnings.
Insulet Stock Summary
Insulet competes with DexCom, Integra LifeSciences, Senseonics Holdings, Edwards Lifesciences, and Tandem Diabetes. Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Insulet Corp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2300 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US45784P1012 |
CUSIP | 45784P101 |
Location | Massachusetts; U.S.A |
Business Address | 100 Nagog Park, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.insulet.com |
Phone | 978 600 7000 |
Currency | USD - US Dollar |
Insulet Key Financial Ratios
Return On Equity | 0.43 | ||||
Profit Margin | 0.20 % | ||||
Operating Margin | 0.16 % | ||||
Price To Sales | 8.66 X | ||||
Revenue | 2.07 B |
Insulet Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 1.9B | 2.0B | 2.3B | 2.6B | 3.1B | 3.2B | |
Net Debt | 96.1M | 457.2M | 727.1M | 711.6M | (869.6M) | (826.1M) | |
Cash | 947.6M | 791.6M | 674.7M | 704.2M | 953.4M | 1.0B | |
Other Assets | 79M | 106.1M | 147.1M | 1.0 | 1.15 | 1.09 | |
Total Liab | 1.3B | 1.5B | 1.8B | 1.9B | 1.9B | 2.0B | |
Total Current Assets | 1.2B | 1.3B | 1.3B | 1.6B | 1.9B | 2.0B | |
Other Current Liab | 132.7M | 162.5M | 306.4M | 382.6M | 424.8M | 446.0M | |
Short Term Debt | 15.6M | 25.1M | 27.5M | 49.4M | 83.8M | 52.1M | |
Retained Earnings | (666.3M) | (649.5M) | (584.3M) | (378M) | 40.3M | 42.3M | |
Accounts Payable | 54.1M | 37.7M | 30.8M | 19.2M | 19.8M | 19.8M | |
Other Current Assets | 63M | 74M | 86.9M | 116.4M | 142M | 149.1M | |
Other Liab | 7M | 17.8M | 14.9M | 8.3M | 9.5M | 5.4M | |
Long Term Debt | 1.0B | 1.2B | 1.4B | 1.4B | 1.3B | 1.4B | |
Net Receivables | 83.8M | 161M | 205.6M | 359.7M | 365.5M | 383.8M | |
Inventory | 154.3M | 303.2M | 346.8M | 402.6M | 430.4M | 451.9M | |
Net Tangible Assets | 22.9M | 535.1M | 479.9M | 349.2M | 401.6M | 421.7M | |
Long Term Debt Total | 887.9M | 1.0B | 1.2B | 1.4B | 1.6B | 1.7B | |
Capital Surpluse | 749M | 1.3B | 1.2B | 1.0B | 1.2B | 899.1M |
Insulet Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 45.1M | 61.2M | 26.7M | 36.2M | 42.7M | 44.8M | |
Operating Income | (600K) | 66.7M | (26.7M) | 220M | 308.9M | 324.3M | |
Ebit | 54.9M | 82.2M | 46.3M | 250.8M | 342.9M | 360.0M | |
Research Development | 146.8M | 160.1M | 180.2M | 205M | 219.6M | 230.6M | |
Ebitda | 110.3M | 139.6M | 109.5M | 323.6M | 423.7M | 444.9M | |
Net Income | 6.8M | 16.8M | 4.6M | 206.3M | 418.3M | 439.2M | |
Total Revenue | 904.4M | 1.1B | 1.3B | 1.7B | 2.1B | 2.2B | |
Gross Profit | 582.3M | 752.1M | 805.6M | 1.2B | 1.4B | 1.5B | |
Cost Of Revenue | 322.1M | 346.7M | 499.7M | 537.2M | 625.9M | 657.2M | |
Income Before Tax | 9.7M | 20.5M | 9.8M | 214.6M | 300.2M | 315.2M | |
Interest Income | 3M | 500K | 9.8M | 28.9M | 39.5M | 41.5M | |
Net Interest Income | (45.1M) | (61.2M) | (26.7M) | (9.8M) | (3.2M) | (3.4M) |
Insulet Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change In Cash | 708.3M | (115.6M) | (116.7M) | 14.5M | 249.2M | 261.7M | |
Free Cash Flow | (82.5M) | (190.8M) | (38.3M) | 36.5M | 305.4M | 320.7M | |
Depreciation | 55.4M | 57.4M | 63.2M | 72.8M | 80.8M | 84.8M | |
Other Non Cash Items | 46M | 41.4M | 12.8M | 8.9M | (1.2M) | (1.1M) | |
Capital Expenditures | 166.5M | 122.7M | 157.3M | 75.6M | 124.9M | 131.1M | |
Net Income | 6.8M | 16.8M | 4.6M | 206.3M | 418.3M | 439.2M | |
End Period Cash Flow | 922M | 806.4M | 689.7M | 704.2M | 953.4M | 1.0B | |
Change To Inventory | (50.5M) | (154.4M) | (49.1M) | (53.6M) | (32.4M) | (34.0M) | |
Net Borrowings | 31.2M | 128.3M | (464.9M) | (39.8M) | (35.8M) | (34.0M) | |
Change To Netincome | 43M | 40M | 81.1M | 47.9M | 55.1M | 40.7M | |
Investments | 180.5M | 40M | (7.8M) | (176.2M) | (146.2M) | (138.9M) |
Insulet Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Insulet's current stock value. Our valuation model uses many indicators to compare Insulet value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Insulet competition to find correlations between indicators driving Insulet's intrinsic value. More Info.Insulet is considered to be number one stock in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.16 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Insulet is roughly 6.33 . At present, Insulet's Return On Equity is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Insulet by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Insulet Systematic Risk
Insulet's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Insulet volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Insulet correlated with the market. If Beta is less than 0 Insulet generally moves in the opposite direction as compared to the market. If Insulet Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Insulet is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Insulet is generally in the same direction as the market. If Beta > 1 Insulet moves generally in the same direction as, but more than the movement of the benchmark.
Insulet Thematic Clasifications
Insulet is part of several thematic ideas from Baby Boomer Prospects to Obamacare Repeal. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Insulet Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Insulet's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Insulet growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Insulet March 17, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Insulet help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Insulet. We use our internally-developed statistical techniques to arrive at the intrinsic value of Insulet based on widely used predictive technical indicators. In general, we focus on analyzing Insulet Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Insulet's daily price indicators and compare them against related drivers.
Information Ratio | 0.0306 | |||
Maximum Drawdown | 9.83 | |||
Value At Risk | (3.03) | |||
Potential Upside | 3.65 |
Complementary Tools for Insulet Stock analysis
When running Insulet's price analysis, check to measure Insulet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insulet is operating at the current time. Most of Insulet's value examination focuses on studying past and present price action to predict the probability of Insulet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insulet's price. Additionally, you may evaluate how the addition of Insulet to your portfolios can decrease your overall portfolio volatility.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |